NEW YORK, Nov. 17, 2017 /PRNewswire/ -- Americord Registry, the fastest growing cord blood bank based in New York City, has announced a significant advancement in stem cell research and clinical trials coming out of Duke University.
The FDA has announced expanded access to Duke University Medical Center for sibling or autologous cord blood infusions for children with cerebral palsy, hydrocephalus, hypoxic brain injury, stroke, apraxia, autism and other brain injuries. The case study expands upon an earlier phase one autism clinical trial involving 25 children using umbilical cord, resulting in observed major improvements in communication, social behavior and overall symptoms.
"I am very excited to see the advancement in clinical trials of cord blood and stem cell research that will benefit those with Autism and Cerebral Palsy," commented Martin Smithmyer, Founder and CEO of Americord. "We are already on the cutting edge of cord blood, cord tissue and placental tissue stem cell technology, and every breakthrough means a better future for those impacted," he continued.
According to the World Health Organization (WHO), 1 in 160 children develops autism. WHO further states that, "based on epidemiological studies conducted over the past 50 years, the prevalence of ASD appears to be increasing globally." The US Center for Disease control asserts, "Cerebral Palsy (CP) is the most common motor disability in childhood." With over one million families banked in the US, the access to this trail has the potential to improve nearly tens of thousands of young lives. To participate in the clinical trial, patients must have their own or a sibling's cord blood preserved in a private bank.
About Americord Registry
Americord is a leader in the advancement of umbilical cord blood, cord tissue, and placenta tissue banking. As a private bank, Americord collects, processes, and stores stem cells for future medical or therapeutic use by the family who saves them. They are committed to pioneering the innovation of new cord blood banking technologies. Under the leadership of Executive Medical Director Dr. Robert Dracker, Americord developed the industry's best value, Cord Blood 2.0™. This revolutionary process collects up to twice as many stem cells compared to the industry standard for cord blood collection. More information is available at www.americordblood.com.
To download the Americord info kit about cord blood banking, please click on the following link: https://compare.americordblood.com/infoguide
CONTACT: Damask Schantz, Damask@americordblood.com, 866-503-6005
SOURCE Americord Registry